（来源：经济参考报） "医保部门始终紧盯前沿医疗技术发展，以政策创新推动技术从临床探索走向规模化应用，脑机接口技 术的支持过程成为典型范例。"谢章澍说。 事实上，早在2025年3月，医保部门就率先设立了脑机接口的相关价格和收费依据，解决了技术应用付 费难题；当年9月实现医保结算赋码，12月已有28个省份制定具体收费项目，推动技术在全国范围内铺 开应用。 "这体现了医保部门对未来产业的前瞻性布局。除脑机接口外，远程操作、质子重离子治疗、CAR-T肿 瘤治疗等一系列新技术、新药品也被纳入医保支持范畴，让群众切实享受到创新成果。"谢章澍表示。 在支持国内创新的同时，医保部门还积极搭建国际化平台，推动中国医药创新成果走向世界。此外，真 实世界医保综合价值评价作为医保目录准入、价格立项等医保决策的重要证据，既为创新技术提供了进 入临床收费的依据，也助力科学定价，为医保基金价值购买服务。 "展望'十五五'，医疗保障部门将继续深化'政策引导'与'价值评价'的双轮驱动战略，继续优化对脑机接 口等创新技术的价格支付政策，并积极开展真实世界医保综合价值评价，为医保决策科学化提供有力支 持。"谢章澍说。 "作为主要的民生保障部门， ...

Core Viewpoint - The article highlights the significant gap in accessibility to advanced medical treatments, particularly for cancer patients, despite improvements in basic medical insurance coverage and the introduction of commercial health insurance as a supplementary option [1][6]. Group 1: Accessibility of Advanced Medical Treatments - Advanced treatments like proton and heavy ion therapy are financially burdensome, with costs reaching approximately 380,000 yuan for patients, which is often unaffordable without insurance [1][5]. - The limited number of hospitals offering such advanced treatments (only about 10 nationwide) exacerbates the accessibility issue [5][6]. - Commercial health insurance is becoming a crucial safety net for families facing high medical costs, with products like "Good Medical Insurance" covering advanced treatments [6][7]. Group 2: Commercial Health Insurance Developments - The recent upgrade of the "Good Medical Insurance" series includes coverage for advanced hospitals and a wide range of innovative drugs, aiming to enhance accessibility to high-quality medical services [3][8]. - The upgraded insurance products cover over 1,500 advanced medical devices and drugs, with a zero deductible policy, allowing for full reimbursement of eligible expenses [9][11]. - The insurance aims to provide a three-tiered protection system: comprehensive basic medication, advanced medical devices for all diseases, and reduced financial burden for serious illnesses [7][9]. Group 3: Market and Policy Implications - The article emphasizes the need for policy guidance and market exploration to ensure that commercial health insurance effectively complements basic medical insurance and addresses the high costs of new drugs and treatments [2][6]. - The anticipated growth in the market for innovative drugs, projected to reach 162 billion yuan in sales by 2024, indicates a significant opportunity for commercial health insurance to expand its role [7][12]. - The upgrade of "Good Medical Insurance" reflects a broader trend towards making high-end medical services more accessible to the general public, aligning with national health improvement goals [11][12].

Core Viewpoint - The article discusses the emerging field of proton and heavy ion therapy as a cutting-edge cancer treatment, highlighting its advantages over traditional radiation therapy, while also addressing the challenges of high costs and limited accessibility for patients [1][2][3]. Group 1: Treatment Overview - Proton and heavy ion therapy utilizes charged particles to target and destroy tumor cells, offering benefits such as reduced side effects and higher tumor control rates compared to conventional radiation therapy [1][3]. - Clinical studies indicate that particle therapy has a five-year overall survival rate of nearly 70% for patients, with specific rates of 92.9% for nasopharyngeal cancer and 70.3% for early-stage non-small cell lung cancer [1][2]. Group 2: Accessibility and Costs - The treatment costs approximately 300,000 yuan per course, which is not covered by health insurance, making it unaffordable for many patients [2][6]. - Only a few thousand patients receive proton and heavy ion therapy annually in China, compared to over 4 million new cancer cases each year, indicating a significant gap in treatment availability [2][6]. Group 3: Technological Development - China has made rapid advancements in proton and heavy ion therapy since the establishment of its first treatment center in 2015, with ongoing efforts to expand the number of treatment facilities [8][9]. - The high cost of equipment and treatment, along with the complexity of the therapy process, limits the number of patients that can be treated each year, with estimates of 1,000 to 1,500 cases annually per facility [10][11]. Group 4: Insurance and Financial Solutions - Approximately 60% of patients self-fund their treatment, while commercial health insurance covers nearly 40% of the costs, highlighting the financial burden on families [15][16]. - Initiatives like the "Shanghai Health Insurance" program include proton and heavy ion therapy, assisting patients with insurance claims and improving treatment accessibility [16][17].